Sai Life Sciences Boosts Veterinary API Production with New Facility

Sai Life Sciences has launched Unit VI, a state-of-the-art facility in Bidar, India, for veterinary API production. This expansion aims to meet the rising global demand for veterinary medicines, utilizing advanced technologies and sustainable practices. The facility aligns with their vision of enhancing niche pharmaceutical offerings.

Hyderabad, Telangana, India – Sai Life Sciences has unveiled Unit VI, a cutting-edge facility dedicated to producing Veterinary Active Pharmaceutical Ingredient (API) in Bidar, India. The company aims to cater to the soaring global demand for veterinary medicines with this new establishment.

Situated next to its flagship API manufacturing site, Unit VI is tailored for veterinary applications, built to uphold the highest standards of safety, sustainability, and regulatory adherence. Krishna Kanumuri, CEO & Managing Director, highlighted the investment's significance in reinforcing their capacity to provide innovative and efficient manufacturing solutions globally.

The new unit leverages advanced technologies, robust supply chain management, and exemplary safety practices, aligning with Sai Life Sciences' strategic goal to excel in high-value pharmaceutical sectors. With over 26 years of experience, the company is a trusted partner in API production, committed to operational excellence and stringent quality standards.

(With inputs from agencies.)